Peptide Association LLC is a for-profit company. We receive compensation from the clinical providers listed on this site. We are not an accrediting body, a licensing board, or a government-affiliated organization. See exactly how we make money.
GHK-Cu
Overview
A naturally occurring copper-binding tripeptide (glycyl-L-histidyl-L-lysine) found in human plasma, saliva, and urine. GHK-Cu activates tissue remodeling by stimulating collagen synthesis, glycosaminoglycan production, and angiogenesis while suppressing fibrinogen synthesis.
Mechanism of Action
It modulates the activity of matrix metalloproteinases and influences over 4,000 genes related to tissue repair.
Research Summary & Key Findings
Studies demonstrate promotion of collagen types I and III synthesis, accelerated wound healing, and increased hair follicle size. Gene expression analysis shows broad regenerative gene activation. Topical application improves skin elasticity, firmness, and reduces photodamage.
Clinical Status
GHK-Cu is in the research phase with limited clinical data in humans. Current evidence is primarily derived from preclinical (animal or in vitro) studies.
Administration Routes
References
Primary literature
- PubMed: "GHK-Cu"
Peer-reviewed literature indexed by the National Library of Medicine.
- ClinicalTrials.gov: "GHK-Cu"
Registered interventional and observational studies, including status and phase.
- PubChem: "GHK-Cu"
Chemical structure, molecular properties, and bioactivity data.
Study-level citations for this compound are being verified against the primary sources before publication. The database queries above return the current indexed literature in the meantime.
Related Peptides in Recovery
BPC-157
Research PhaseA synthetic gastric pentadecapeptide derived from a protein found in human gastric juice. BPC-157 promotes angiogenesis ...
View detailsTB-500 (Thymosin Beta-4)
In Clinical TrialsThymosin Beta-4 is a 43-amino acid actin-sequestering protein involved in cell migration, differentiation, and tissue re...
View detailsDSIP (Delta Sleep-Inducing Peptide)
Research PhaseA naturally occurring nonapeptide (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) originally isolated from cerebral venous blood o...
View detailsPentosan Polysulfate (Elmiron)
FDA ApprovedA semi-synthetic sulfated polysaccharide derived from beechwood hemicellulose with structural similarities to glycosamin...
View detailsNo lawful pathway today
GHK-Cu is not FDA-approved and does not currently have a lawful prescription or compounding pathway in the United States, so there is nothing for us to sell you here and no consultation to book. That can change: eight peptides moved back to a lawful pathway in February 2026.
Tell me if the status changes
One email, only if this compound's regulatory standing actually moves. Not a newsletter, not a sales sequence.
Join the Association
Access exclusive peptide protocols, provider resources, and community support.
List Your PracticeDisclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed.